Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology firm focused on developing innovative molecular glue degrader-based therapies, has announced its participation in several upcoming investor conferences. These include the Credit Suisse 31st Annual Healthcare Conference from November 7-10, the Jefferies 13th Annual London Healthcare Conference from November 15-17, and the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1. Archived webcasts will be available on the company's investor site.

Monte Rosa leverages its proprietary QuEEN™ platform for protein degradation in drug discovery.

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences:

• Credit Suisse 31^st Annual Healthcare Conference (Nov. 7-10) 
• Jefferies 13^th Annual London Healthcare Conference (Nov. 15-17) 
• Piper Sandler 34^th Annual Healthcare Conference (Nov. 29-Dec. 1)
  

Where applicable, archived webcasts can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and MGD drug candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com. 

Contacts:

Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com

FAQ

What investor conferences will Monte Rosa Therapeutics (GLUE) attend in November 2022?

Monte Rosa Therapeutics (GLUE) will attend the Credit Suisse 31st Annual Healthcare Conference (Nov. 7-10), Jefferies 13th Annual London Healthcare Conference (Nov. 15-17), and Piper Sandler 34th Annual Healthcare Conference (Nov. 29-Dec. 1) in November 2022.

Where can I access archived webcasts of Monte Rosa Therapeutics events?

Archived webcasts of Monte Rosa Therapeutics events can be accessed in the 'Events & Presentations' section of their investor site.

What is the focus of Monte Rosa Therapeutics' research?

Monte Rosa Therapeutics focuses on developing novel molecular glue degrader (MGD) medicines that selectively eliminate therapeutically relevant proteins.

What is the QuEEN™ platform developed by Monte Rosa Therapeutics?

The QuEEN™ platform is a proprietary technology developed by Monte Rosa Therapeutics for the quantitative and engineered elimination of neosubstrates in drug discovery.